Rivaroxaban and Vitamin K Antagonists for the Anticoagulation for the Implantation of Vena Cava Filters

Launched by SECOND AFFILIATED HOSPITAL, SCHOOL OF MEDICINE, ZHEJIANG UNIVERSITY · Aug 22, 2019

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness and safety of two types of blood-thinning medications: new oral anticoagulants and vitamin K antagonists. These medications will be tested in patients who have been diagnosed with deep vein thrombosis (a condition where blood clots form in the deep veins, often in the legs) and who are undergoing a procedure to implant a special device called a vena cava filter. This filter helps prevent blood clots from traveling to the lungs, which can be very serious.

To be eligible for this trial, participants must be between the ages of 18 and 75 and have been diagnosed with deep venous thrombosis, specifically when a retrievable vena cava filter is being placed. However, there are some important exclusions, such as individuals with certain serious health issues, pregnant or breastfeeding women, and those taking specific medications that could interfere with the study. If you choose to participate, you will receive detailed information about the treatments and what to expect throughout the study. Your safety and health will be monitored closely during the trial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients who was diagnosed with deep venous thrombosis of the lower extremity and implanted with a retrievable inferior vena cava filter.
• Exclusion Criteria:
• • Age \< 18 years or age \> 75 years,
• • With obvious contraindications for anticoagulation therapy,
• • Allergic to iodine contrast agents in the past,
• • Pregnant or breastfeeding women,
• • With malignant tumors and life expectancy \< 1 year,
• • Severe liver diseases (such as acute hepatitis, chronic active hepatitis or cirrhosis) or alanine aminotransferase levels were higher than three times the upper limit of normal.
• • With other diseases that need anticoagulation,
• • With previous heparin-induced thrombocytopenia,
• • Bacterial endocarditis,
• • Systolic blood pressure \> 180 mmHg or diastolic blood pressure \> 110 mmHg,
• • Taking cytochrome P450 3A4(CYP-450 3A4) inhibitors or inducers
• • With severe renal insufficiency (creatinine clearance \<30 mL/min)
• • Allergic to the drug used in this study
• • With permanent filter implantation